CDK4 and glioblastoma: Just recently, we described the successful elimination of patient-derived two-dimensional (2D)- and three-dimensional (3D)-cultured GBM cells by the global CDKi dinaciclib as well as the selective CDK4/6 inhibitor abemaciclib [16, 17].